In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on TFF Pharmaceuticals (TFFP), with a price target of $31.00. The company’s shares closed last Friday at $16.89.
According to TipRanks.com, Selvaraju is a top 25 analyst with an average return of 54.1% and a 81.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, NeuroBo Pharmaceuticals, and Inovio Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TFF Pharmaceuticals with a $28.33 average price target, representing a 63.8% upside. In a report issued on February 19, B.Riley Financial also reiterated a Buy rating on the stock with a $36.00 price target.
See today’s analyst top recommended stocks >>
Based on TFF Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.06 million. In comparison, last year the company had a GAAP net loss of $2.84 million.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TFFP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TFF Pharmaceuticals, Inc. operates as an early-stage biopharmaceutical company. It develops and commercializes drug products based on its Thin film Freezing (TFF) technology platform. The firm also engages in research, development & drug formulation and initial testing of drug products. The company was founded in 2005 and is headquartered in Toronto, Canada.
